It should be noted that despite PSA being the most widely available, and cited, biomarker for prostate cancer, taken alone it may not be an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials, which has not been proven to be a suitable replacement for a final survival endpoint [89]. The gene discussed is KLK3; the disease is prostate carcinoma.